Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.

Advertisement

Related Content

Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says
CMS Lacks Authority To Exempt Part B Drugs From Sequester Cuts – Tavenner
Sequester May Further Depress AmerisourceBergen’s Oncology Drug Sales
Raising Part D Donut Hole Discounts To 75% Proposed By President
Raising Part D Donut Hole Discounts To 75% Proposed By President
CMS Bound To Current Approach To Sequester Cuts For Part B Drugs, Agency Says
Bill Revising ASP Calculation Surfaces Again In House; Medicare Cost Question Remains

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel